Short-term improvement of mental health after a COVID-19 vaccination

Charilaos Chourpiliadis¹, Anikó Lovik¹, Anna K. Kähler², Unnur A. Valdimarsdóttir^{1,3,4}, Emma M. Frans²,
Fredrik Nyberg⁵, Patrick F. Sullivan^{2,6}, Fang Fang¹

¹Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

²Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

³Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland

⁴Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, Massachusetts, USA

⁵School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

⁶Departments of Genetics and Psychiatry, University of North Carolina, Chapel Hill, North Carolina, USA

Correspondence to:

Charilaos Chourpiliadis, Institute of Environmental Medicine, Karolinska Institutet, Box 210, 171 77 Stockholm, email: charilaos.chourpiliadis@ki.se

Key points

Question: Is COVID-19 vaccination associated with a short-term change in mental health?

Findings: This longitudinal study included 7,925 Swedish adults with self-reported COVID-19 vaccination and symptoms of mental health responding from December 2020 to October 2021. The prevalence of depressive or anxiety symptoms was lower one month after vaccination compared to one month before vaccination. The effect size was greater among individuals receiving two doses of vaccine, compared with those receiving only one dose.

Meaning: Receiving vaccination against COVID-19 is associated with short-term improvement in mental health.

Abstract

Importance: The role of COVID-19 vaccination on the mental health of the general population remains poorly understood.

Objective: To assess the short-term change of depressive and anxiety symptoms in relation to COVID-19 vaccination among Swedish adults.

Design: A prospective cohort study with monthly data collections on self-reported depressive and anxiety symptoms from December 2020 to October 2021 and COVID-19 vaccination from July to October 2021.

Setting: The Omtanke2020 Study, Sweden.

Participants: 7,925 participants of the Omtanke2020 study with complete data on depressive and anxiety symptoms and vaccination status.

Intervention(s) or Exposure(s): Receiving the first or second dose of a COVID-19 vaccine.

Main outcomes(s) and Measure(s): Binary measures of depression (PHQ-9, cut-off ≥ 10) and anxiety (GAD-7, cut-off ≥ 10) one month before the first dose, one month after the first dose, and, if applicable, one month after the second dose. For individuals not vaccinated or chose to not report vaccination status (unvaccinated individuals), we selected three monthly measures of PHQ-9 and GAD-7 with 2-month intervals in-between based on data availability.

Results: 5,079 (64.1%) individuals received two doses of COVID-19 vaccine, 1,977 (24.9%) received one dose, 305 (3.9%) were not vaccinated, and 564 (7.1%) chose not to report vaccination status. There was a lower prevalence of depression and anxiety among vaccinated, compared with unvaccinated, individuals, especially after the second dose. Among individuals receiving two doses of vaccine, the prevalence of depression and anxiety was lower after both first (aRR=0.82, 95%CI 0.76-0.88 for depression; aRR=0.81, 95%CI 0.73-0.89 for anxiety) and second (aRR=0.79, 95%CI 0.73-0.85 for depression; aRR=0.73, 95%CI 0.66-0.81 for anxiety) dose, compared with before vaccination. Similar results were observed among individuals receiving only one dose (aRR=0.76, 95%CI 0.68-0.84 for depression; aRR=0.82, 95%CI 0.72-0.94 for anxiety, comparing after first dose to before vaccination). These results were independent of age, sex, recruitment type, body mass index, smoking, relationship status, history of psychiatric disorder, number of comorbidities, COVID-19 infection status, and seasonality.

Conclusions and Relevance: We observed a positive short-term change in depressive and anxiety symptoms among adults receiving a COVID-19 vaccine in the current pandemic.

Introduction

The COVID-19 pandemic has caused an unprecedented health crisis worldwide. The negative mental health impact of the pandemic has been demonstrated, affecting both the infected and non-infected individuals (1, 2). Vaccination against COVID-19 has been suggested to have a beneficial impact on mental health, in addition to protection from severe infection (3). However, the existing evidence rests on a restricted phase of the vaccine rollout (4) and studies with relatively small sample size (5).

Our aim was to provide an estimate of the short-term change in mental health after the vaccination against COVID-19, specifically depression and anxiety, during a long phase of the vaccine rollout and using a large study sample with careful adjustment for the impact of age, sex, history of COVID-19 infection, etc. We hypothesized that receiving a COVID-19 vaccine was associated with a decrease in the prevalence of depressive and anxiety symptoms.

Methods

We performed a longitudinal study based on the Omtanke2020 study, an ongoing prospective cohort study specifically designed to assess the mental health impact of COVID-19 in Sweden (6). Over 28,000 adult Swedish residents were recruited to Omtanke2020 between June 2020 and June 2021 and provided self-reported data on mental and physical health, sociodemographic factors, lifestyle factors, and COVID-19-specific questions such as infection and vaccination (6, 7).

In the present study, we included all participants of Omtanke2020 with monthly data on depressive and anxiety symptoms between December 2020 and October 2021. These participants also had to have data on COVID-19 vaccination collected between 17th July and 30th October 2021. We excluded from the analysis 40 participants with inconsistent information on vaccination (e.g., time of the 2nd dose preceding that of the 1st dose) and 22 participants who received the 1-dose Janssen vaccine. We defined the vaccinated individuals as those reporting having received two doses or one dose of a COVID-19 vaccine, and the unvaccinated individuals as those reporting no vaccination or chose not to report vaccination status.

The Patient Health Questionnaire (PHQ-9) (8) was used to measure depressive symptoms whereas the Generalized Anxiety Disorder (GAD-7) (9) scale was used to measure anxiety symptoms. The binary outcomes of depression and anxiety were calculated from the total scores of these scales, which are shown to have appropriate psychometric properties in Omtanke2020 (6). A cut-off of 10 in each scale was used to define significant depressive or anxiety symptoms, respectively (8, 9).

For vaccinated individuals, we considered depression and anxiety at three timepoints: one month before 1st dose (baseline), first month after the first dose, and, if applicable, first month after the second dose. For unvaccinated individuals, we randomly selected three timepoints with a 2-month interval in-between during the study period (i.e., baseline/Time 0, 2 months after baseline/Time 1, and 4 months after baseline/Time 2).

We first used Poisson regression to calculate prevalence ratio, comparing the prevalence of depression and anxiety between vaccinated and unvaccinated individuals, at baseline, after 1st dose/Time 1, and after 2nd dose/Time 2. To disentangle the seasonality effect from the vaccine effect, we performed a stratified analysis by calendar month. We first calculated crude prevalence ratio and then adjusted the analysis for age, sex, body mass index (BMI), recruitment type (self-recruitment or by invitation), relationship status, current smoking, number of comorbidities, history of psychiatric disorder, history of COVID-19 infection, and month of baseline survey.

We also used a Generalized Estimating Equations (GEE) model to assess the temporal change in the prevalence of depression and anxiety among vaccinated and unvaccinated individuals separately. In this analysis, we adjusted for age, sex, BMI, recruitment type, relationship status, current smoking, number of comorbidities, history of psychiatric disorder, history of COVID-19 infection, and month of baseline survey and used robust standard error to correct for the overestimated standard error of a log-Poisson model with binary outcome (10).

Results

A total of 7,925 individuals, with a mean age of 52.6 (± 15.4) years and 83% women, were included in the analysis, including 5,079 (64.09%) with two doses and 1,977 (24.95%) with one dose of COVID-19 vaccine, 305 (3.85%) not vaccinated, and 564 (7.12%) not reporting vaccination status (Table 1).

Although there tended to be a lower prevalence of depression and anxiety among the vaccinated individuals, compared with the unvaccinated individuals, already at baseline, the difference became greater after the 2nd dose among those with two doses of vaccine and after the 1st dose among those with one dose of vaccine (Table 1). The stratified analysis by calendar month showed a similar result pattern across different calendar months (Supplementary Table 1).

Figure 1 shows the risk ratio (RR) of depression and anxiety, comparing the prevalence of depression and anxiety after a COVID-19 vaccine (1st or 2nd dose) to the prevalence before vaccination or the prevalence at later time points (Time 1 or 2) to the prevalence at first time point (Time 0) among the unvaccinated individuals. There was a decline in the prevalence of depression and anxiety among individuals that received two doses of vaccine, both during the month after 1st dose (aRR=0.82; 95%CI: 0.76-0.88 for depression; aRR=0.81; 95%CI: 0.73-0.89 for anxiety) and during the month after 2nd dose (aRR=0.79; 95%CI: 0.73-0.85 for depression; aRR=0.73; 95%CI: 0.66-0.81 for anxiety). A decrease in prevalence was also noted during the month after the 1st dose among individuals that received only one dose of vaccine (aRR=0.76; 95%CI: 0.68-0.84 for depression; aRR=0.82; 95%CI: 0.72-0.94 for anxiety). Among the unvaccinated individuals, there was no statistically significant decrease in the prevalence of depression or anxiety over time, except when comparing the prevalence of depression at Time 2 to that of Time 0.

Discussion

The present study demonstrated a short-term improvement in the prevalence of depression and anxiety after COVID-19 vaccination in a large sample of Swedish adults. The improvement was more pronounced after the second dose, compared with the first dose, and was independent of age, sex, history of COVID-19 infection, etc.

Our results are consistent with previous research suggesting a positive influence of COVID-19 vaccination on mental health (3-5, 11). The present study extends however the existing knowledge by addressing several methodological issues of previous studies, such as cross-sectional study design (5, 11), relatively small sample size (5), the use of a single mental health instrument (e.g., PHQ-4) (3, 4, 11), and addressing a restricted phase of vaccination, e.g., March 2021 (3) or June 2021 (4). First, our study used a longitudinal design with monthly surveys on vaccination status and mental health which allowed us to understand the effect of COVID-19 vaccine on the temporal change of depression and anxiety as well as to disentangle the effect of vaccine from seasonal variation in the prevalence of depression and anxiety. The large sample size, the study of both depression and anxiety using well-established instruments, and the relatively long duration of the study period are other strengths. Limitations of the study include self-reported data on COVID-19 vaccination and depressive and anxiety symptoms. Finally, whether our results are generalizable to other populations remains to be studied due to the largely different burden of pandemic and population coverage of COVID-19 vaccination across the globe.

Conclusion

We found an immediate positive change in symptoms of depression and anxiety after receiving a COVID-19 vaccination among adults in the current pandemic.

Acknowledgement

This study was supported by NordForsk (project No. 105668) and Horizon2020 (CoMorMent, 847776). The authors also thank the participants of Omtanke2020.

Conflict of Interest

The authors declare no conflict of interest.

Ethical approval

The study was approved (DNR 2020-01785) by the Swedish Ethical Review Authority on 3 June 2020.

References

1. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *The Lancet Psychiatry*. 2021;8(5):416-27.
2. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet*. 2021;398(10312):1700-12.
3. Perez-Arce F, Angrisani M, Bennett D, Darling J, Kapteyn A, Thomas K. COVID-19 vaccines and mental distress. *PLoS One*. 2021;16(9):e0256406.
4. Koltai J, Raifman J, Bor J, McKee M, Stuckler D. Does COVID-19 vaccination improve mental health? A difference-in-difference analysis of the Understanding Coronavirus in America study. *medRxiv*. 2021. 10.1101/2021.07.19.21260782
5. Yuan Y, Deng Z, Chen M, Yin D, Zheng J, Liu Y, et al. Changes in Mental Health and Preventive Behaviors before and after COVID-19 Vaccination: A Propensity Score Matching (PSM) Study. *Vaccines (Basel)*. 2021;9(9).
6. Lovik A, González-Hijón J, Kähler AK, Valdimarsdóttir UA, Frans EM, Magnusson PKE, et al. Mental health indicators in Sweden over a 12-month period during the COVID-19 pandemic. *medRxiv*. 2021:2021.12.10.21267338.
7. Unnarsdóttir AB, Lovik A, Fawns-Ritchie C, Ask H, Köiv K, Hagen K, et al. Cohort Profile: COVIDMENT: COVID-19 cohorts on mental health across six nations. *Int J Epidemiol*. 2021.
8. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606-13.
9. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092-7.
10. Mansournia MA, Nazemipour M, Naimi AI, Collins GS, Campbell MJ. Reflection on modern methods: demystifying robust standard errors for epidemiologists. *Int J Epidemiol*. 2021;50(1):346-51.
11. Bilge Y, Keles E, Baydili KN. The Impact of COVID-19 Vaccination on Mental Health. *Journal of Loss and Trauma* 2021.

Table 1. Baseline characteristics of the study participants by vaccination status.

	All participants	Two doses of vaccine	One dose of vaccine	Not vaccinated	Vaccination status not reported
No. (%)	7925 (100%)	5079 (64.09%)	1977 (24.95%)	305 (3.85%)	564 (7.11%)
Age (years), No. (%)					
18-29	698 (8.81%)	412 (8.11%)	199 (10.12%)	36 (11.80%)	51 (9.04%)
30-39	1110 (14.01%)	681 (13.41%)	293 (14.82%)	56 (18.36%)	80 (14.18%)
40-49	1411 (17.80%)	811 (15.97%)	390 (19.73%)	71 (23.28%)	139 (24.65%)
50-59	1806 (22.79%)	1080 (21.26%)	524 (26.50%)	71 (23.28%)	131 (23.23%)
60-69	1601 (20.20%)	1100 (21.66%)	360 (18.21%)	50 (16.39%)	91 (16.13%)
70+	1299 (16.39%)	995 (19.59%)	211 (10.67%)	21 (6.89%)	72 (12.77%)
Sex, No. (%)					
Men	1350 (17.03%)	925 (18.21%)	285 (14.42%)	41 (13.44%)	99 (17.55%)
Women	6575 (82.97%)	4154 (81.79%)	1692 (85.58%)	264 (86.56%)	465 (82.45%)
Recruitment type, No. (%)					
By invitation	4325 (54.57%)	3068 (60.41%)	850 (42.99%)	149 (48.85%)	258 (45.74%)
Self-recruitment	3600 (45.43%)	2011 (39.59%)	1127 (57.01%)	156 (51.15%)	306 (54.26%)
Body mass index (Kg/m²), No. (%)					
<18.5, underweight	121 (1.53%)	71 (1.40%)	36 (1.82%)	6 (1.97%)	8 (1.42%)
18.5-25, normal weight	4190 (52.87%)	2727 (53.69%)	1016 (51.39%)	156 (51.15%)	291 (51.60%)
>25-30, overweight	2333 (29.44%)	1504 (29.61%)	575 (29.08%)	93 (30.49%)	161 (28.55%)
>30, obese	943 (11.90%)	567 (11.16%)	257 (13%)	35 (11.48%)	84 (14.89%)
Missing	338 (4.26%)	210 (4.13%)	93 (4.70%)	15 (4.92%)	20 (3.55%)
Number of comorbidities, No. (%)					
None	5338 (67.36%)	3391 (66.77%)	1363 (68.94%)	208 (68.20%)	376 (66.67%)
1	1910 (24.10%)	1225 (24.12%)	469 (23.72%)	77 (25.25%)	139 (24.65%)
2	491 (6.20%)	332 (6.54%)	110 (5.56%)	13 (4.26%)	36 (6.38%)
≥3	167 (2.11%)	118 (2.32%)	33 (1.67%)	7 (2.30%)	9 (1.60%)
Missing	19 (0.24%)	13 (0.26%)	2 (0.10%)	0 (0.00%)	4 (0.71%)
History of psychiatric disorder, No. (%)					
No	5480 (69.15%)	3644 (71.75%)	1288 (65.15%)	184 (60.33%)	364 (64.54%)
Yes	2352 (29.68%)	1375 (27.07%)	673 (34.04%)	117 (38.36%)	187 (33.16%)
Missing	93 (1.17%)	60 (1.18%)	16 (0.81%)	4 (1.31%)	13 (2.30%)
Current smoking, No. (%)					
No	6901 (87.08%)	4468 (87.97%)	1698 (85.89%)	259 (84.92%)	476 (84.40%)
Yes	989 (12.48%)	588 (11.58%)	274 (13.86%)	44 (14.43%)	83 (14.72%)
Missing	35 (0.44%)	23 (0.45%)	5 (0.25%)	2 (0.66%)	5 (0.89%)
Relationship status, No. (%)					
Single	2178 (27.48%)	1361 (26.80%)	579 (29.29%)	97 (31.80%)	141 (25.00%)
In a relationship	5714 (72.10%)	3703 (72.91%)	1385 (70.06%)	206 (67.54%)	420 (74.47%)
Missing	33 (0.42%)	15 (0.30%)	13 (0.66%)	2 (0.66%)	3 (0.53%)
History of COVID-19 infection, No. (%)					
Not infected	4183 (52.78%)	2732 (53.79%)	1047 (52.96%)	155 (50.82%)	249 (44.15%)
Infected, not hospitalized	3340 (42.15%)	2106 (41.46%)	817 (41.33%)	134 (43.93%)	283 (50.18%)
Infected, hospitalized	402 (5.07%)	241 (4.75%)	113 (5.72%)	16 (5.25%)	32 (5.67%)

Table 2. Prevalence ratio (PR) and 95% confidence interval (CI) of depression and anxiety comparing vaccinated to unvaccinated individuals

Depression				
	Prevalence in unvaccinated; N (%)	Prevalence in individuals with 2 doses; N (%)	Crude PR (95%CI)	Adjusted PR (95%CI)*
Baseline	182 (20.9%)	675 (13.3%)	0.64 (0.55 - 0.74)	0.74 (0.61 - 0.90)
After 1st dose or 2 months after baseline	173 (19.9%)	551 (10.8%)	0.55 (0.47 - 0.64)	0.77 (0.62 - 0.96)
After 2nd dose or 4 months after baseline	157 (18.1%)	534 (10.5%)	0.58 (0.45 - 0.69)	0.65 (0.52 - 0.81)
	Prevalence in unvaccinated; N (%)	Prevalence in individuals with 1 dose; N (%)	Crude PR (95%CI)	Adjusted PR (95%CI)+
Baseline	182 (20.9%)	343 (17.4%)	0.83 (0.71 - 0.97)	0.86 (0.67 - 1.10)
After 1st dose or 2 months after baseline	173 (19.9%)	262 (13.3%)	0.67 (0.56 - 0.79)	0.71 (0.53 - 0.95)
Anxiety				
	Prevalence in unvaccinated; N (%)	Prevalence in individuals with 2 doses; N (%)	Crude PR (95%CI)	Adjusted PR (95%CI)*
Baseline	103 (11.9%)	466 (9.2%)	0.77 (0.63 - 0.95)	0.76 (0.58 - 1.00)
After 1st dose or 2 months after baseline	123 (14.2%)	382 (7.5%)	0.53 (0.44 - 0.64)	0.69 (0.52 - 0.91)
After 2nd dose or 4 months after baseline	106 (12.2%)	343 (6.7%)	0.55 (0.45 - 0.68)	0.59 (0.44 - 0.81)
	Prevalence in unvaccinated; N (%)	Prevalence in individuals with 1 dose; N (%)	Crude PR (95%CI)	Adjusted PR (95%CI)+
Baseline	103 (11.9%)	233 (11.8%)	0.99 (0.80 - 1.24)	1.10 (0.76 - 1.58)
After 1st dose or 2 months after baseline	123 (14.2%)	186 (9.4%)	0.67 (0.537 - 0.823)	0.75 (0.52 - 1.06)

Analysis was performed using Poisson regression and adjusted for age, sex, recruitment type, body mass index, relationship status, current smoking, number of comorbidities, history of psychiatric disorder, history of COVID-19 infection, and month of baseline survey.

*The analysis of adjusted RR included 817 unvaccinated and 4,807 vaccinated individuals.

+The analysis of adjusted PR included 817 unvaccinated and 1,858 vaccinated individuals.

Figure 1. Risk Ratio (RR) of depression and anxiety, comparing the prevalence of depression and anxiety after COVID-19 vaccine (1st or 2nd dose) to the prevalence before vaccine among vaccinated individuals, and comparing the prevalence of later time points to baseline among the unvaccinated individuals. Unvaccinated individuals include individuals reporting no vaccination or chose to not report vaccination status. The analyses were performed using GEE models and adjusted for age, sex, recruitment type, body mass index, relationship status, current smoking, number of comorbidities, history of psychiatric disorder, history of COVID-19 infection, and month of baseline survey